HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors

Abstract

The epidermal growth factor receptor (EGFR) is overexpressed and activated in many human cancers and predicts poor patient prognosis. Targeting the kinase domain with specific EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib has been used in anticancer treatments. However, patient response rates in different human cancers were initially… (More)
DOI: 10.1038/onc.2012.396

Topics

8 Figures and Tables